The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more ...

AHA urges HHS to block Novo Nordisk's 340B data demand, citing legal and cost concerns for safety-net hospitals and covered entities.

A new report paints a stark picture of how a subset of large healthcare providers are drawing the lion’s share of 340B savings within a single state.  | A Minnesota analysis of providers' reported ...

The hospital lobby is asking federal officials to head off expanded data collection policies some drugmakers are implementing for providers participating in the 340B drug discount program.

AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.

The drug discount program is under scrutiny on a variety of fronts ...

AbbVie loses bid to block Tennessee 340B law as federal court upholds state statute limiting drugmaker restrictions on contract pharmacies.

On July 31, 2025, the Health Resources and Services Administration (HRSA) released long-awaited guidance establishing a 340B Rebate Model Pilot Program (Pilot Program). The announcement marks a ...

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...